Document text
Machine-read from the scan, so expect some errors. Lines that couldn’t be read are left out.
Page 1
U.S. ARMY MEDICAL DEPARTMENT CENTER AND SCHOOL FORT SAM HOUSTON, TEXAS 78234-6100 MEMORANDUM FOR Commanders, All HSC Hospitals and Health Clinics SUBJECT: Human Radiation Research 1. Reference memorandum, AMEDD Center & School, HSMC-GCI, 2 8 Jan 94, subject: Human Radiation Research. 2. The Assistant to the Secretary of Defense for Atomic Energy coordinates DOD‘s inquiry into human radiation research. He recently directed that the DOD inquiry cover the period from the 1 9 4 4 to the present, not the 1 9 4 4 to 1 9 7 4 interval we requested in our original memorandum, referenced above. 3 . Please relay this change to the responsible project officer for your medical treatment facility (MTF). While the change in period of inquiry greatly expands the number of pertinent clinical investigations involving ionizing radiation, projects considered by human-use committees from 1 9 8 0 to the present are recorded in an electronic database to which we have access. 4. Your new mission is to report all research involving human exposure to ionizing radiation between 1 9 4 4 and 1979, plus any research from 1 9 8 0 to the present not considered by a human-use committee convened under AR 40-38. Report sufficient detail that the American public is satisfied with the thoroughness of your search at your facility. 5. To date, we know the identity of only nine project officers, out of 62 facilities addressed. Please assure that your project officer has identified himself or herself to us. Respond with name, title, unit, mailing address, and voice and fax telephone numbers to DSN 471-2511, commercial 210-221-2511, voice mail 471- or 210-221-9212, or fax 210-554-4756. 6. If your list of project titles exceeds 1 page in length, submit a labeled Advance copies may be sent by telefacsimile, if desired. Note that the fourth line of the first paragraph of enclosure 2-2 of the referenced memorandum 7. Congressional interest in this subject continues to be strong. In the event your MTF finds so many records that it cannot complete its inquiry by 1 March 1994, provide an interim report by the suspense date, with a full report as soon as possible. Negative responses are required if you find no records. 8. Information and assistance may be obtained by contacting MAJ John D. Grabenstein, Regulatory Affairs Pharmacist, at DSN 471-2511, commercial 210221-2511, voice mail 471- or 210-221-9212, or fax 210-554-4756. Chief, Clinical Investigation Consultant to The Surgeon General for Clinical Investigation